At a crossroads: Human DNA tumor viruses and the host DNA damage response

Future Virology

Volumn 6, Issue 7, 2011, Pages 813-830

  Nikitin, Pavel A ^a   Luftig, Micah A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

DNA tumor virus; EBV; Epstein Barr virus; genomic instability; HBV; hepatitis B virus; HPV; human papillomavirus; human polyomavirus; Kaposi's sarcoma associated herpesvirus; KSHV; oncogenic; stress; tumor suppression

Indexed keywords

ATR PROTEIN; DNA; PROTEIN P53; VIRUS DNA;

B LYMPHOCYTE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; DNA DAMAGE; DNA STRUCTURE; GENE EXPRESSION; GENOMIC INSTABILITY; HUMAN; HUMAN HERPESVIRUS 8; KERATINOCYTE; MUTAGENESIS; NONHUMAN; PAPILLOMAVIRUS INFECTION; POLYOMA VIRUS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR VIRUS; VIRUS REACTIVATION; VIRUS REPLICATION; WART VIRUS;

HEPATITIS B VIRUS; HUMAN HERPESVIRUS 4; HUMAN HERPESVIRUS 8; HUMAN PAPILLOMAVIRUS; POLYOMAVIRUS;

EID: 79960428356     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.11.55     Document Type: Review

References (145)

1. Bartkova J, Rezaei N, Liontos M et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444(7119), 633-637 (2006). (Pubitemid 44864442)
2. Di Micco R, Fumagalli M, Cicalese A et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 444(7119), 638-642 (2006). (Pubitemid 44864443)
3. Zindy F, Williams RT, Baudino TA et al. Arf tumor suppressor promoter monitors latent oncogenic signals in vivo. Proc. Natl Acad. Sci. USA 100(26), 15930-15935 (2003). (Pubitemid 38021092)
4. Bartkova J, Horejsi Z, Koed K et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434(7035), 864-870 (2005). (Pubitemid 40558993)
5. Gorgoulis VG, Vassiliou LV, Karakaidos P et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434(7035), 907-913 (2005). (Pubitemid 40559004)
6. Ditullio RA Jr, Mochan TA, Venere M et al. 53BP1 functions in an ATM-dependent checkpoint pathway that is constitutively activated in human cancer. Nat. Cell Biol. 4(12), 998-1002 (2002). (Pubitemid 35469432)
7. Zou L, Elledge SJ. Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. Science 300(5625), 1542-1548 (2003). (Pubitemid 36682880)
8. Lee JH, Ghirlando R, Bhaskara V, Hoffmeyer MR, Gu J, Paull TT. Regulation of Mre11/Rad50 by Nbs1: effects on nucleotide-dependent DNA binding and association with ataxia-telangiectasia-like disorder mutant complexes. J. Biol. Chem. 278(46), 45171-45181 (2003). (Pubitemid 37432650)
9. Khanna KK, Jackson SP. DNA double-strand breaks: signaling, repair and the cancer connection. Nat. Genet. 27(3), 247-254 (2001). (Pubitemid 32201842)
10. Cimprich KA, Cortez D. ATR: an essential regulator of genome integrity. Nat. Rev. Mol. Cell. Biol. 9(8), 616-627 (2008). (Pubitemid 352032926)
11. Ciccia A, Elledge SJ. The DNA damage response: making it safe to play with knives. Mol Cell 40(2), 179-204 (2010).
12. Kumagai A, Dunphy WG. Claspin, a novel protein required for the activation of Chk1 during a DNA replication checkpoint response in Xenopus egg extracts. Mol. Cell 6(4), 839-849 (2000).
13. Lee JH, Paull TT. Direct activation of the ATM protein kinase by the Mre11/ Rad50/Nbs1 complex. Science 304(5667), 93-96 (2004). (Pubitemid 38451463)
14. Schultz LB, Chehab NH, Malikzay A, Halazonetis TD. p53 binding protein 1 (53BP1) is an early participant in the cellular response to DNA double-strand breaks. J. Cell Biol. 151(7), 1381-1390 (2000). (Pubitemid 32047588)
15. Stewart GS, Wang B, Bignell CR, Taylor AM, Elledge SJ. MDC1 is a mediator of the mammalian DNA damage checkpoint. Nature 421(6926), 961-966 (2003). (Pubitemid 36288029)
16. Halazonetis TD, Gorgoulis VG, Bartek J. An oncogene-induced DNA damage model for cancer development. Science 319(5868), 1352-1355 (2008). (Pubitemid 351354863)
17. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability - an evolving hallmark of cancer. Nat. Rev. Mol. Cell. Biol. 11(3), 220-228 (2010).
18. Weitzman MD, Lilley CE, Chaurushiya MS. Genomes in conflict: maintaining genome integrity during virus infection. Annu. Rev. Microbiol. 64, 61-81 (2010).
19. Dheekollu J, Deng Z, Wiedmer A, Weitzman MD, Lieberman PM. A role for MRE11, NBS1, and recombination junctions in replication and stable maintenance of EBV episomes. PLoS One 2(12), E1257 (2007).
20. Stracker TH, Carson CT, Weitzman MD. Adenovirus oncoproteins inactivate the Mre11-Rad50-NBS1 DNA repair complex. Nature 418(6895), 348-352 (2002). (Pubitemid 34790688)
21. Weiden MD, Ginsberg HS. Deletion of the E4 region of the genome produces adenovirus DNA concatemers. Proc. Natl Acad. Sci. USA 91(1), 153-157 (1994). (Pubitemid 24018661)
22. Carson CT, Orazio NI, Lee DV et al. Mislocalization of the MRN complex prevents ATR signaling during adenovirus infection. EMBO J 28(6), 652-662 (2009).
23. Mohni KN, Livingston CM, Cortez D, Weller SK. ATR and ATRIP are recruited to herpes simplex virus type 1 replication compartments even though ATR signaling is disabled. J. Virol. 84(23), 12152-12164 (2010).
24. Tarakanova VL, Leung-Pineda V, Hwang S et al. g-herpesvirus kinase actively initiates a DNA damage response by inducing phosphorylation of H2AX to foster viral replication. Cell Host Microbe 1(4), 275-286 (2007). (Pubitemid 46865610)
25. Tarakanova VL, Stanitsa E, Leonardo SM, Bigley TM, Gauld SB. Conserved gherpesvirus kinase and histone variant H2AX facilitate gherpesvirus latency in vivo. Virology 405(1), 50-61 (2010).
26. Rickinson A, Kieff E. Epstein-Barr virus. In:Fields Virology . Knipe DM, Howley PM (Eds).Lippincott Williams & Wilkins, PA, USA, 2603-2654 (2006).
27. Yates JL, Warren N, Sugden B. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 313(6005), 812-815 (1985). (Pubitemid 15130835)
28. Kaiser C, Laux G, Eick D, Jochner N, Bornkamm GW, Kempkes B. The proto-oncogene c-Myc is a direct target gene of Epstein-Barr virus nuclear antigen 2. J. Virol. 73(5), 4481-4484 (1999). (Pubitemid 29189900)
29. Johannsen E, Miller CL, Grossman SR, Kieff E. EBNA-2 and EBNA-3C extensively and mutually exclusively associate with RBPJk in Epstein-Barr virus-transformed B lymphocytes. J. Virol. 70(6), 4179-4183 (1996).
30. Zhao B, Marshall DR, Sample CE. A conserved domain of the Epstein-Barr virus nuclear antigens 3A and 3C binds to a discrete domain of Jk. J. Virol. 70(7), 4228-4236 (1996). (Pubitemid 26187423)
31. Lin J, Johannsen E, Robertson E, Kieff E. Epstein-Barr virus nuclear antigen 3C putative repression domain mediates coactivation of the LMP1 promoter with EBNA-2. J. Virol. 76(1), 232-242 (2002). (Pubitemid 33139008)
32. Cahir Mcfarland ED, Izumi KM, Mosialos G. Epstein-Barr virus transformation: involvement of latent membrane protein 1-mediated activation of NF-kB. Oncogene 18(49), 6959-6964 (1999).
33. Miller CL, Burkhardt AL, Lee JH et al. Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. Immunity 2(2), 155-166 (1995).
34. Babcock GJ, Hochberg D, Thorley-Lawson AD. The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. Immunity 13(4), 497-506 (2000).
35. Tovey MG, Lenoir G, Begon-Lours J. Activation of latent Epstein-Barr virus by antibody to human IgM. Nature 276(5685), 270-272 (1978). (Pubitemid 9053904)
36. Feederle R, Kost M, Baumann M et al. The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators. EMBO J. 19(12), 3080-3089 (2000). (Pubitemid 30386778)
37. Henderson E, Miller G, Robinson J, Heston L. Efficiency of transformation of lymphocytes by Epstein-Barr virus. Virology 76(1), 152-163 (1977). (Pubitemid 8031103)
38. Sugden B, Mark W. Clonal transformation of adult human leukocytes by Epstein-Barr virus. J. Virol. 23(3), 503-508 (1977). (Pubitemid 8172767)
39. Nikitin PA, Yan CM, Forte E et al. An ATM/ Chk2-mediated DNA damage-responsive signaling pathway suppresses Epstein-Barr virus transformation of primary human B cells. Cell Host Microbe 8(6), 510-522 (2010).
40. Lacoste S, Wiechec E, dos Santos Silva AG et al. Chromosomal rearrangements after ex vivo Epstein-Barr virus (EBV) infection of human B cells. Oncogene 29, 503-515 (2010).
41. Nilsson K. Human B-lymphoid cell lines. Hum Cell 5(1), 25-41 (1992).
42. Woisetschlaeger M, Yandava CN, Furmanski LA, Strominger JL, Speck SH. Promoter switching in Epstein-Barr virus during the initial stages of infection of B lymphocytes. Proc. Natl Acad. Sci. USA 87(5), 1725-1729 (1990).
43. Skalska L, White RE, Franz M, Ruhmann M, Allday MJ. Epigenetic repression of p16(INK4A) by latent Epstein-Barr virus requires the interaction of EBNA3A and EBNA3C with CtBP. PLoS Pathog. 6(6), E1000951 (2010).
44. Maruo S, Zhao B, Johannsen E, Kieff E, Zou J, Takada K. Epstein-Barr virus nuclear antigens 3C and 3A maintain lymphoblastoid cell growth by repressing p16INK4A and p14ARF expression. Proc. Natl Acad. Sci. USA 108(5), 1919-1924 (2011).
45. Yi F, Saha A, Murakami M et al. Epstein-Barr virus nuclear antigen 3C targets p53 and modulates its transcriptional and apoptotic activities. Virology 388(2), 236-247 (2009).
46. Choudhuri T, Verma SC, Lan K, Murakami M, Robertson ES. The ATM/ATR signaling effector Chk2 is targeted by Epstein-Barr virus nuclear antigen 3C to release the G2/M cell cycle block. J. Virol. 81(12), 6718-6730 (2007). (Pubitemid 46878076)
47. Kamranvar SA, Gruhne B, Szeles A, Masucci MG. Epstein-Barr virus promotes genomic instability in Burkitt's lymphoma. Oncogene 26(35), 5115-5123 (2007). (Pubitemid 47206955)
48. Gruhne B, Sompallae R, Masucci MG. Three Epstein-Barr virus latency proteins independently promote genomic instability by inducing DNA damage, inhibiting DNA repair and inactivating cell cycle checkpoints. Oncogene 28(45), 3997-4008 (2009).
49. Gruhne B, Sompallae R, Marescotti D, Kamranvar SA, Gastaldello S, Masucci MG. The Epstein-Barr virus nuclear antigen-1 promotes genomic instability via induction of reactive oxygen species. Proc. Natl Acad. Sci. USA 106(7), 2313-2318 (2009).
50. Wade M, Allday MJ. Epstein-Barr virus suppresses a G(2)/M checkpoint activated by genotoxins. Mol. Cell. Biol. 20(4), 1344-1360 (2000). (Pubitemid 30069255)
51. Liu MT, Chen YR, Chen SC et al. Epstein- Barr virus latent membrane protein 1 induces micronucleus formation, represses DNA repair and enhances sensitivity to DNA-damaging agents in human epithelial cells. Oncogene 23(14), 2531-2539 (2004).
52. Dhar SK, Yoshida K, Machida Y et al. Replication from oriP of Epstein-Barr virus requires human ORC and is inhibited by geminin. Cell 106(3), 287-296 (2001). (Pubitemid 32772613)
53. Chaudhuri B, Xu H, Todorov I, Dutta A, Yates JL. Human DNA replication initiation factors, ORC and MCM, associate with oriP of Epstein-Barr virus. Proc. Natl Acad. Sci. USA 98(18), 10085-10089 (2001). (Pubitemid 32802978)
54. Deng Z, Lezina L, Chen CJ, Shtivelband S, So W, Lieberman PM. Telomeric proteins regulate episomal maintenance of Epstein-Barr virus origin of plasmid replication. Mol. Cell. 9(3), 493-503 (2002). (Pubitemid 34273781)
55. Deng Z, Atanasiu C, Burg JS, Broccoli D, Lieberman PM. Telomere repeat binding factors TRF1, TRF2, and hRAP1 modulate replication of Epstein-Barr virus OriP. J. Virol. 77(22), 11992-12001 (2003). (Pubitemid 37339853)
56. Tempera I, Deng Z, Atanasiu C, Chen CJ, D'erme M, Lieberman PM. Regulation of Epstein-Barr virus OriP replication by poly(ADP-ribose) polymerase 1. J. Virol. 84(10), 4988-4997 (2010).
57. Deng Z, Atanasiu C, Zhao K et al. Inhibition of Epstein-Barr virus OriP function by tankyrase, a telomere-associated poly-ADP ribose polymerase that binds and modifies EBNA1. J. Virol. 79(8), 4640-4650 (2005). (Pubitemid 40464215)
58. Kudoh A, Fujita M, Zhang L et al. Epstein- Barr virus lytic replication elicits ATM checkpoint signal transduction while providing an S-phase-like cellular environment. J. Biol. Chem. 280(9), 8156-8163 (2005). (Pubitemid 40349716)
59. Kudoh A, Iwahori S, Sato Y et al. Homologous recombinational repair factors are recruited and loaded onto the viral DNA genome in Epstein-Barr virus replication compartments. J. Virol. 83(13), 6641-6651 (2009).
60. Gastaldello S, Hildebrand S, Faridani O et al. A deneddylase encoded by Epstein-Barr virus promotes viral DNA replication by regulating the activity of cullin-RING ligases. Nat. Cell Biol. 12(4), 351-361 (2010).
61. Mauser A, Saito S, Appella E, Anderson CW, Seaman WT, Kenney S. The Epstein-Barr virus immediate-early protein BZLF1 regulates p53 function through multiple mechanisms. J. Virol. 76(24), 12503-12512 (2002). (Pubitemid 35386936)
62. Bailey SG, Verrall E, Schelcher C, Rhie A, Doherty AJ, Sinclair AJ. Functional interaction between Epstein-Barr virus replication protein Zta and host DNA damage response protein 53BP1. J. Virol. 83(21), 11116-11122 (2009).
63. Chang Y, Cesarman E, Pessin MS et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266(5192), 1865-1869 (1994).
64. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N. Engl. J. Med. 332(18), 1186-1191 (1995).
65. Lagunoff M, Bechtel J, Venetsanakos E et al. De novo infection and serial transmission of Kaposi's sarcoma-associated herpesvirus in cultured endothelial cells. J. Virol. 76(5), 2440-2448 (2002). (Pubitemid 34150712)
66. Staskus KA, Zhong W, Gebhard K et al. Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells. J. Virol. 71(1), 715-719 (1997). (Pubitemid 26412345)
67. Chandriani S, Ganem D. Array-based transcript profiling and limiting-dilution reverse transcription-PCR analysis identify additional latent genes in Kaposi's sarcoma-associated herpesvirus. J. Virol. 84(11), 5565-5573 (2010).
68. Ballestas ME, Chatis PA, Kaye KM. Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen. Science 284(5414), 641-644 (1999). (Pubitemid 29289588)
69. Friborg J, Jr., Kong W, Hottiger MO, Nabel GJ. p53 inhibition by the LANA protein of KSHV protects against cell death. Nature 402(6764), 889-894 (1999).
70. Chipuk JE, Green DR. Dissecting p53- dependent apoptosis. Cell Death Differ. 13(6), 994-1002 (2006).
71. Chen W, Hilton IB, Staudt MR, Burd CE, Dittmer DP. Distinct p53, p53:LANA, and LANA complexes in Kaposi's sarcoma-associated herpesvirus lymphomas. J. Virol. 84(8), 3898-3908 (2010).
72. Radkov SA, Kellam P, Boshoff C. The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells. Nat. Med. 6(10), 1121-1127 (2000).
73. Verma SC, Borah S, Robertson ES. Latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus up-regulates transcription of human telomerase reverse transcriptase promoter through interaction with transcription factor Sp1. J. Virol. 78(19), 10348-10359 (2004). (Pubitemid 39258360)
74. Mesri EA, Cesarman E, Boshoff C. Kaposi's sarcoma and its associated herpesvirus. Nat. Rev. Cancer 10(10), 707-719 (2010).
75. Chang Y, Moore PS, Talbot SJ et al. Cyclin encoded by KS herpesvirus. Nature 382(6590), 410 (1996).
76. Verschuren EW, Klefstrom J, Evan GI, Jones N. The oncogenic potential of Kaposi's sarcoma-associated herpesvirus cyclin is exposed by p53 loss in vitro and in vivo. Cancer Cell 2(3), 229-241 (2002). (Pubitemid 41043978)
77. Liu L, Eby MT, Rathore N, Sinha SK, Kumar A, Chaudhary PM. The human herpes virus 8-encoded viral FLICE inhibitory protein physically associates with and persistently activates the Ik B kinase complex. J. Biol. Chem. 277(16), 13745-13751 (2002). (Pubitemid 34967977)
78. Guasparri I, Keller SA, Cesarman E. KSHV vFLIP is essential for the survival of infected lymphoma cells. J. Exp. Med. 199(7), 993-1003 (2004). (Pubitemid 38481090)
79. Koopal S, Furuhjelm JH, Jarviluoma A et al. Viral oncogene-induced DNA damage response is activated in Kaposi sarcoma tumorigenesis. PLoS Pathog. 3(9), 1348-1360 (2007). (Pubitemid 47510286)
80. Verschuren EW, Hodgson JG, Gray JW, Kogan S, Jones N, Evan GI. The role of p53 in suppression of KSHV cyclin-induced lymphomagenesis. Cancer Res. 64(2), 581-589 (2004). (Pubitemid 38120897)
81. Cuomo ME, Knebel A, Morrice N, Paterson H, Cohen P, Mittnacht S. p53-driven apoptosis limits centrosome amplification and genomic instability downstream of NPM1 phosphorylation. Nat. Cell Biol. 10(6), 723-730 (2008). (Pubitemid 351772938)
82. Sarek G, Jarviluoma A, Moore HM et al. Nucleophosmin phosphorylation by v-cyclin-CDK6 controls KSHV latency. PLoS Pathog. 6(3), E1000818 (2010).
83. Shin YC, Nakamura H, Liang X et al. Inhibition of the ATM/p53 signal transduction pathway by Kaposi's sarcoma-associated herpesvirus interferon regulatory factor 1. J. Virol. 80(5), 2257-2266 (2006). (Pubitemid 43271532)
84. Walboomers JM, Jacobs MV, Manos MM et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189(1), 12-19 (1999). (Pubitemid 29406813)
85. Howley PM, Lowy DR. Papillomaviridae. In:Fields virology. (5th Edition). Knipe DM, Howley PM (Eds).Lippincott Williams & Wilkins, PA, USA, 2299-2354 (2007).
86. Flores ER, Lambert PF. Evidence for a switch in the mode of human papillomavirus type 16 DNA replication during the viral life cycle. J. Virol. 71(10), 7167-7179 (1997). (Pubitemid 27391650)
87. Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat. Rev. Cancer 10(8), 550-560 (2010).
88. Mohr IJ, Clark R, Sun S, Androphy EJ, Macpherson P, Botchan MR. Targeting the E1 replication protein to the papillomavirus origin of replication by complex formation with the E2 transactivator. Science 250(4988), 1694-1699 (1990). (Pubitemid 120031873)
89. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63(6), 1129-1136 (1990). (Pubitemid 120035062)
90. Munger K, Werness BA, Dyson N, Phelps WC, Harlow E, Howley PM. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J. 8(13), 4099-4105 (1989). (Pubitemid 20066852)
91. Dyson N, Howley PM, Munger K, Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243(4893), 934-937 (1989). (Pubitemid 19066153)
92. Cheng S, Schmidt-Grimminger DC, Murant T, Broker TR, Chow LT. Differentiation-dependent up-regulation of the human papillomavirus E7 gene reactivates cellular DNA replication in suprabasal differentiated keratinocytes. Genes Dev. 9(19), 2335-2349 (1995).
93. Dowhanick JJ, Mcbride AA, Howley PM. Suppression of cellular proliferation by the papillomavirus E2 protein. J. Virol. 69(12), 7791-7799 (1995).
94. Moody CA, Laimins LA. Human papillomaviruses activate the ATM DNA damage pathway for viral genome amplification upon differentiation. PLoS Pathog. 5(10), E1000605 (2009).
95. Phelps WC, Yee CL, Munger K, Howley PM. The human papillomavirus type 16 E7 gene encodes transactivation and transformation functions similar to those of adenovirus E1A. Cell 53(4), 539-547 (1988).
96. Bester AC, Roniger M, Oren YS et al. Nucleotide deficiency promotes genomic instability in early stages of cancer development. Cell 145(3), 435-446 (2011).
97. Duensing S, Duensing A, Lee DC et al. Cyclin-dependent kinase inhibitor indirubin- 3′-oxime selectively inhibits human papillomavirus type 16 E7-induced numerical centrosome anomalies. Oncogene 23(50), 8206-8215 (2004). (Pubitemid 39531832)
98. Park JW, Pitot HC, Strati K et al. Deficiencies in the Fanconi anemia DNA damage response pathway increase sensitivity to HPV-associated head and neck cancer. Cancer Res. 70(23), 9959-9968 (2010).
99. Moody CA, Fradet-Turcotte A, Archambault J, Laimins LA. Human papillomaviruses activate caspases upon epithelial differentiation to induce viral genome amplification. Proc. Natl Acad. Sci. USA 104(49), 19541-19546 (2007).
100. Kusumoto-Matsuo R, Kanda T, Kukimoto I. Rolling circle replication of human papillomavirus type 16 DNA in epithelial cell extracts. Genes Cells 16(1), 23-33 (2011).
101. Kadaja M, Isok-Paas H, Laos T, Ustav E, Ustav M. Mechanism of genomic instability in cells infected with the high-risk human papillomaviruses. PLoS Pathog. 5(4), E1000397 (2009).
102. Seeger C, Zoulim F, Mason WS. Hepadnaviridae. In:Fields Virology (5th Edition). Knipe DM, Howley PM (Eds).Lippincott Williams & Wilkins, PA, USA, 2977-3031 (2007).
103. Matsuda Y, Ichida T. Impact of hepatitis B virus X protein on the DNA damage response during hepatocarcinogenesis. Med. Mol. Morphol. 42(3), 138-142 (2009).
104. Zhao F, Hou NB, Yang XL et al. Ataxia telangiectasia-mutated-Rad3-related DNA damage checkpoint signaling pathway triggered by hepatitis B virus infection. World J. Gastroenterol. 14(40), 6163-6170 (2008).
105. Zheng Z, Li J, Sun J et al. Inhibition of HBV replication by theophylline. Antiviral Res. 89(2), 149-155 (2011).
106. Kew MC. Hepatitis B virus X protein in the pathogenesis of hepatitis B virus-induced hepatocellular carcinoma. J. Gastroenterol. Hepatol. 26(Suppl. 1), 144-152 (2011).
107. Wu XY, Qian JJ, Lin Y, Zheng MH. Hepatitis B virus X protein disrupts DNA interstrand crosslinking agent mitomycin C induced ATR dependent intra-S-phase checkpoint. Eur. J. Cancer 44(11), 1596-1602 (2008).
108. Studach L, Wang WH, Weber G et al. Polo-like kinase 1 activated by the hepatitis B virus X protein attenuates both the DNA damage checkpoint and DNA repair resulting in partial polyploidy. J. Biol. Chem. 285(39), 30282-30293 (2010).
109. Kwon JA, Rho HM. Transcriptional repression of the human p53 gene by hepatitis B viral core protein (HBc) in human liver cells. Biol. Chem. 384(2), 203-212 (2003). (Pubitemid 36348319)
110. Lee SG, Rho HM. Transcriptional repression of the human p53 gene by hepatitis B viral X protein. Oncogene 19(3), 468-471 (2000). (Pubitemid 30077349)
111. Wang XW, Gibson MK, Vermeulen W et al. Abrogation of p53-induced apoptosis by the hepatitis B virus X gene. Cancer Res. 55(24), 6012-6016 (1995).
112. Elmore LW, Hancock AR, Chang SF et al. Hepatitis B virus X protein and p53 tumor suppressor interactions in the modulation of apoptosis. Proc. Natl Acad. Sci. USA 94(26), 14707-14712 (1997). (Pubitemid 28041438)
113. Takada S, Kaneniwa N, Tsuchida N, Koike K. Cytoplasmic retention of the p53 tumor suppressor gene product is observed in the hepatitis B virus X gene-transfected cells. Oncogene 15(16), 1895-1901 (1997). (Pubitemid 27480677)
114. Ueda H, Ullrich SJ, Gangemi JD et al. Functional inactivation but not structural mutation of p53 causes liver cancer. Nat. Genet. 9(1), 41-47 (1995).
115. Wang XW, Forrester K, Yeh H, Feitelson MA, Gu JR, Harris CC. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc. Natl Acad. Sci. USA 91(6), 2230-2234 (1994). (Pubitemid 24092077)
116. Becker SA, Lee TH, Butel JS, Slagle BL. Hepatitis B virus X protein interferes with cellular DNA repair. J. Virol. 72(1), 266-272 (1998). (Pubitemid 28048836)
117. Lee TH, Elledge SJ, Butel JS. Hepatitis B virus X protein interacts with a probable cellular DNA repair protein. J. Virol. 69(2), 1107-1114 (1995).
118. Jia L, Wang XW, Harris CC. Hepatitis B virus X protein inhibits nucleotide excision repair. Int. J. Cancer 80(6), 875-879 (1999). (Pubitemid 29108863)
119. Jaitovich-Groisman I, Benlimame N, Slagle BL et al. Transcriptional regulation of the TFIIH transcription repair components XPB and XPD by the hepatitis B virus X protein in liver cells and transgenic liver tissue. J. Biol. Chem. 276(17), 14124-14132 (2001).
120. Qadri I, Fatima K, Abde LHH. Hepatitis B virus X protein impedes the DNA repair via its association with transcription factor, TFIIH. BMC Microbiol. 11, 48 (2011).
121. Forgues M, Marrogi AJ, Spillare EA et al. Interaction of the hepatitis B virus X protein with the Crm1-dependent nuclear export pathway. J. Biol. Chem. 276(25), 22797-22803 (2001).
122. Livezey KW, Negorev D, Simon D. Increased chromosomal alterations and micronuclei formation in human hepatoma HepG2 cells transfected with the hepatitis B virus HBX gene. Mutat. Res. 505(1-2), 63-74 (2002).
123. Yun C, Cho H, Kim SJ, Lee JH, Park SY, Chan GK. Mitotic aberration coupled with centrosome amplification is induced by hepatitis B virus X oncoprotein via the Ras-mitogen-activated protein/extracellular signal-regulated kinase-mitogen-activated protein pathway. Mol. Cancer Res. 2(3), 159-169 (2004). (Pubitemid 39030306)
124. Rakotomalala L, Studach L, Wang WH, Gregori G, Hullinger RL, Andrisani O. Hepatitis B virus X protein increases the Cdt1-to-geminin ratio inducing DNA re-replication and polyploidy. J. Biol. Chem. 283(42), 28729-28740 (2008).
125. Imperiale MJ, Major EO. Polyomaviridae. In:Fields Virology (5th Edition). Knipe DM, Howley PM (Eds).Lippincott Williams & Wilkins, PA, USA, 2263-2298 (2007).
126. Abend JR, Jiang M, Imperiale MJ. BK virus and human cancer: innocent until proven guilty. Semin. Cancer Biol. 19(4), 252-260 (2009).
127. Maginnis MS, Atwood WJ. JC virus: an oncogenic virus in animals and humans? Semin. Cancer Biol. 19(4), 261-269 (2009).
128. Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 319(5866), 1096-1100 (2008). (Pubitemid 351300792)
129. Shuda M, Feng H, Kwun HJ et al. T antigen mutations are a human tumor-specific signature for Merkel cell polyomavirus. Proc. Natl Acad. Sci. USA 105(42), 16272-16277 (2008).
130. Lanson NA Jr, Egeland DB, Royals BA, Claycomb WC. The MRE11-NBS1-RAD50 pathway is perturbed in SV40 large T antigen-immortalized AT-1, AT-2 and HL-1 cardiomyocytes. Nucleic Acids Res. 28(15), 2882-2892 (2000). (Pubitemid 30599262)
131. Digweed M, Demuth I, Rothe S et al. SV40 large T-antigen disturbs the formation of nuclear DNA-repair foci containing MRE11. Oncogene 21(32), 4873-4878 (2002).
132. Zhao X, Madden-Fuentes RJ, Lou BX et al. Ataxia telangiectasia-mutated damage-signaling kinase- and proteasome-dependent destruction of Mre11-Rad50-Nbs1 subunits in simian virus 40-infected primate cells. J. Virol. 82(11), 5316-5328 (2008). (Pubitemid 351705239)
133. Wu X, Avni D, Chiba T et al. SV40 T antigen interacts with Nbs1 to disrupt DNA replication control. Genes Dev. 18(11), 1305-1316 (2004). (Pubitemid 38720598)
134. Dahl J, You J, Benjamin TL. Induction and utilization of an ATM signaling pathway by polyomavirus. J. Virol. 79(20), 13007-13017 (2005). (Pubitemid 41433220)
135. Boichuk S, Hu L, Hein J, Gjoerup OV. Multiple DNA damage signaling and repair pathways deregulated by simian virus 40 large T antigen. J. Virol. 84(16), 8007-8020 (2010).
136. Rohaly G, Korf K, Dehde S, Dornreiter I. Simian virus 40 activates ATR-d p53 signaling to override cell cycle and DNA replication control. J. Virol. 84(20), 10727-10747 (2010).
137. Decaprio JA, Ludlow JW, Figge J et al. SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell 54(2), 275-283 (1988).
138. Dyson N, Bernards R, Friend SH et al. Large T antigens of many polyomaviruses are able to form complexes with the retinoblastoma protein. J. Virol. 64(3), 1353-1356 (1990). (Pubitemid 20087779)
139. Si H, Robertson ES. Kaposi's sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen induces chromosomal instability through inhibition of p53 function. J. Virol. 80(2), 697-709 (2006). (Pubitemid 43062883)
140. Shi Y, Dodson GE, Shaikh S, Rundell K, Tibbetts RS. Ataxia- telangiectasia-mutated (ATM) is a T-antigen kinase that controls SV40 viral replication in vivo. J. Biol. Chem. 280(48), 40195-40200 (2005). (Pubitemid 41779156)
141. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 140(6), 883-899 (2010).
142. Brummelkamp TR, Fabius AW, Mullenders J et al. An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors. Nat. Chem. Biol. 2(4), 202-206 (2006).
143. Forte E, Luftig MA. MDM2-dependent inhibition of p53 is required for Epstein-Barr virus B-cell growth transformation and infected-cell survival. J. Virol. 83(6), 2491-2499 (2009).
144. Sarek G, Kurki S, Enback J et al. Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas. J. Clin. Investig. 117(4), 1019-1028 (2007). (Pubitemid 46556758)
145. Petre CE, Sin SH, Dittmer DP. Functional p53 signaling in Kaposi's sarcoma-associated herpesvirus lymphomas: implications for therapy. J. Virol. 81(4), 1912-1922 (2007).(Pubitemid 46214463)